Cite
Pharmacogenomics of 17-alpha hydroxyprogesterone caproate for recurrent preterm birth: a case-control study.
MLA
Manuck, T. A., et al. “Pharmacogenomics of 17-Alpha Hydroxyprogesterone Caproate for Recurrent Preterm Birth: A Case-Control Study.” BJOG: An International Journal of Obstetrics & Gynaecology, vol. 125, no. 3, Feb. 2018, pp. 343–50. EBSCOhost, https://doi.org/10.1111/1471-0528.14485.
APA
Manuck, T. A., Watkins, W. S., Esplin, M. S., Biggio, J., Bukowski, R., Parry, S., Zhan, H., Huang, H., Andrews, W., Saade, G., Sadovsky, Y., Reddy, U. M., Ilekis, J., Yandell, M., Varner, M. W., Jorde, L. B., the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Genomics and Proteomics Network for Preterm Birth Research (GPN‐PBR), & Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Genomics and Proteomics Network for Preterm Birth Research (GPN-PBR). (2018). Pharmacogenomics of 17-alpha hydroxyprogesterone caproate for recurrent preterm birth: a case-control study. BJOG: An International Journal of Obstetrics & Gynaecology, 125(3), 343–350. https://doi.org/10.1111/1471-0528.14485
Chicago
Manuck, T. A., W. S. Watkins, M. S. Esplin, J. Biggio, R. Bukowski, S. Parry, H. Zhan, et al. 2018. “Pharmacogenomics of 17-Alpha Hydroxyprogesterone Caproate for Recurrent Preterm Birth: A Case-Control Study.” BJOG: An International Journal of Obstetrics & Gynaecology 125 (3): 343–50. doi:10.1111/1471-0528.14485.